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may be ascribed to patient selection, increased myocardial energy expenditure and oxygen
consumption, or to specific mechanisms of action. Both sympathomimetic amines and type III
phosphodiesterase inhibitors act through an increase in intracellular cyclic adenosine
monophoshate and free calcium concentrations, mechanisms that increase oxygen consumption
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been improved by the administration of neurohormonal
antagonists and the use of implantable cardioverter
defibrillators and cardiac resynchronization devices.1-4
However, these therapies only slow HF progression; and
many patients progress to a stage of advanced HF,
characterized by severe cardiac dysfunction, severe
symptoms, and poor prognosis.5,6 At this stage, impaired
left ventricular (LV) pump function plays a pivotal role as
a cause of dyspnea and fatigue, poor peripheral perfusion,
and end-organ dysfunction.7 Improvement in cardiac
function through agents with inotropic properties is,
therefore, an attractive option for such patients as the
most reliable means for improving cardiac output andlict of Interest: see page 104.
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11.03.011peripheral perfusion. However, all currently available
inotropic agents have adverse effects; and their use has
been associated with increased mortality.8-11 An ideal
inotropic agent able to restore tissue perfusion in the
absence of adverse effects is not available, but new agents
with different biologic targets and better safety profiles are
under development.The clinical problem
Fluid overload and pulmonary congestion with elevated
LV end-diastolic pressure and pulmonary wedge pressures
are the main causes of HF hospitalizations.3,12-14 Reduced
cardiac output and peripheral hypoperfusion may also be
important in some patients. These patients, whose
prevalence can be estimated at approximately 10% to
15% of the overall patients admitted for acute HF, have
low blood pressure, signs of kidney and/or liver
dysfunction, and severe LV systolic and diastolic97
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uretics or vasodilators
cannot consistently im-
prove the hemodynamic
abnormalities of these
patients, and their ad-
ministration may further
decrease blood pressure
and peripheral perfusion
and worsen myocardial
ischemia and/or renal
damage.6,10 Agents with
inotropic properties are
the only agents that can
improve LV systolic
function and cardiac out-
put and, hence, end-
organ perfusion in such
patients. Unfortunately,
most, if not all, of the
inotropic agents have
been associated with
untoward effects on out-
comes. Thus, their ad-
ministration may allow
short-term improvement
in hemodynamic parame-
ters and symptoms with
longer term harm. Newer
inotropic agents, with a
better benefit-to-risk ratio,
are clearly needed.Inotropic therapy
in current guidelines
Inotropic agents are
indicated for the treat-
ment for patients with
peripheral hypoperfu-
sion and fluid overload
secondary to cardiac
dysfunction (“cold andwet patients”) (Table 1).8-11,15 Hypotension is the primary
sign of hypoperfusion and low cardiac output.6,10,16
Other signs of hypoperfusion include cold, clammy skin,
renal impairment, liver dysfunction, and/or impaired
mentation. Clinical assessment is sufficient when urgent
treatment is needed. Echocardiography, when available,
should show signs of systolic dysfunction with dilated,
hypokinetic ventricles. Until agents with predominant
effects on diastolic function become available, it is
unlikely that inotropic agents may be useful in patients
with HF and preserved LV ejection fraction (LVEF). To
minimize their untoward effects, inotropic agents shouldbe administered at the lowest effective doses and dis-
continued as soon as organ perfusion is restored and/or
congestion is relieved.
The current American College of Cardiology/American
Heart Association guidelines state that inotropic agents are
indicated to improve symptoms and end-organ function in
patients with low output syndrome, LV systolic dysfunc-
tion, and systolic blood pressure (SBP) less than 90 mm
Hg despite adequate filling pressure.1 Inotropic agents
may also be indicated as bridge to heart transplant or
mechanical assist device implantation or as palliation for
symptoms in end-stage HF.17
These indications are in agreement with the European
Society of Cardiology guidelines, which state that
inotropic agents are indicated for patients with low SBP
or a low measured cardiac index in the presence of signs of
hypoperfusion or congestion. They also state that inotropic
agents should be reserved for patients with dilated,
hypokinetic ventricles and, when indicated, should be
administered as early as possible and discontinued as soon
as organ perfusion is restored and/or congestion is
reduced.2,18 Differences in the indications to different
inotropic agents are outlined in these guidelines with
levosimendan indicated also for patients with a SBP
greater than 100 mm Hg and dopamine indicated for
patients with a SBP less than 90 mm Hg.2
The Heart Failure Society of America guidelines
expand the indication of inotropic agents also to patients
with evidence of fluid overload and lack of response to
intravenous (IV) diuretics and/or to patients with reduced
or worsening renal function. Regarding safety, the Heart
Failure Society of America guidelines state that the
administration of inotropic agents should be accompanied
by continuous monitoring of blood pressure and cardiac
rhythm with drug withdrawal or dose reduction to be
considered in case of symptomatic hypotension or
development of tachyarrhythmias.3
Despite consistency between different guidelines, recent
registries have shown wide variations in the proportion of
patients receiving inotropic agents. The proportion of patients
hospitalized for acute HF and receiving inotropic agents
ranges from 7% in the Organized Program to Facilitate Life-
Saving Treatment in Hospitalized Patients with Heart Failure
(OPTIMIZE-HF) registry16 to nearly 25% in the EuroHeart
Failure Survey II.19 Although low SBP is considered a major
indication for inotropic agents, this does not seem to occur in
clinical practice16,19,20 so that patients may receive inotropic
agents even in the absence of clear indications.Current inotropic agents
Dobutamine
Dobutamine is the prototype of inotropic agents acting
through β-adrenergic receptor (AR) stimulation (Table 2).
It has high affinity for β1-ARs whose stimulation causes
Table 1
Recommendations for treatment with inotropic agents according to current major guidelines for the treatment of HF (shown in alphabetical order)
Society Indications
Class of Recommendation –
Level of Evidence
American College of Cardiology
Foundation/American
Heart Association1
Clinical evidence of hypoperfusion with hypotension and elevated cardiac
filling pressures (eg, elevated jugular venous pressure and/or pulmonary
wedge pressure)→ to maintain systemic perfusion and preserve end-organ
performance, while more definitive therapy is considered.
I – C
Palliation of symptoms in patients with refractory end-stage HF. IIb – B
Routine intermittent infusions are not recommended for patients with
refractory end-stage HF.
III – A
Use in normotensive patients with acute decompensated HF without
evidence of decreased organ perfusion is not recommended.
III – B
European Society of Cardiology2 Low output state (low SBP and/or measured CI) + signs of hypoperfusion or
congestion despite the use of vasodilators and/or diuretics + dilated,
hypokinetic ventricles to improve symptoms
IIa – B
Administered as early as possible/withdrawn as early as organ perfusion is
restored and/or congestion reduced
Heart Failure Society of America3 Patients with advanced HF and low output syndrome; particularly if SBPb90
mm Hg and/or symptomatic hypotension despite adequate filling pressure.
C
Patients with evidence of fluid overload if they respond poorly to IV diuretics
or have diminished or worsening renal function.
C
Not recommended unless left heart filling pressures elevated/CI severely
impaired, based on direct measurement or clear clinical signs.
C
Administration in the setting of acute decompensated HF should be
accompanied by continuous or frequent BP monitoring and continuous
monitoring of cardiac rhythm.
C
If symptomatic hypotension or worsening tachyarrhythmias develop
during administration, discontinuation or dose reduction should be considered.
C
Abbreviation: BP, blood pressure.
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(cAMP) concentration with secondary protein kinase
activation, sarcolemma calcium-channel opening, and
sarcoplasmic reticulum (SR) calcium release. Calcium
binding to troponin C removes the inhibitory effect of
troponin I and allows actin myosin interaction and
sarcomere contraction. The increase in the intracellular
cAMP and calcium concentrations plays, therefore, a
pivotal role for the dobutamine inotropic effects.
Dobutamine administration has beneficial short-term
hemodynamic effects with an increase in cardiac output
and decrease in pulmonary wedge pressure in patients with
HF. However, it also increases the heart rate and the
conduction velocity in the atrioventricular node, with
increased heart rate in patients with atrial fibrillation.18,21Table 2
Inotropic agents currently available
Drug Mechanism
Dobutamine Predominant β1-AR agonis
and α1-AR agonist properti
Dopamine DA1-DA2, β1-AR, α-AR1
Milrinone/enoximone PDE3-Is
Levosimendan (not available in the US) Myofilament Ca2+ sensitize
ATP-sensitive K+ channel a
PDE-I
Abbreviations: DA, dopaminergic; ESC, European Society of Cardiology.Dependency on β1-ARs is a major limitation of this agent.
The hemodynamic response to dobutamine can be blunted
by concomitant β-blocker therapy and β-AR down-
regulation, and this causes interindividual variability in
the response to dobutamine.22,23 As β1-AR down-
regulation is secondary to prolonged exposure to the
agonist, tolerance development with decrease in the
hemodynamic response to dobutamine has been described
after days of continuous dobutamine infusion.24
Dobutamine has a milder effect on β2-ARs, which
cause vascular smooth muscle relaxation. This effect is
partially counterbalanced by α-1 AR stimulation so that
dobutamine net effects on the peripheral vessels are of
mild vasodilation or neutral. α-1–Mediated peripheral
vasoconstriction can be shown during concomitant β2-Class of Recommendation – Level of Evidence
(According to 2008 ESC guidelines)
t with β2-AR
es
IIa – B
agonist IIb – C
IIb – B
r IIa – B
ctivator
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carvedilol receive dobutamine infusion.22
Dobutamine administration has been associated with an
increased risk of death. The first study showing this was a
retrospective analysis from the Flolan International
Randomized Survival trial (FIRST). This was a random-
ized controlled trial of continuous IV epoprostenol plus
conventional therapy vs conventional therapy alone, in
patients with advanced HF, prematurely terminated for a
strong trend toward decreased survival in the patients
treated with epoprostenol. An analysis of the patients
included in this trial showed that those on dobutamine
infusion (mean dose, 9 μg/kg per minute; range, 5-12 μg/
kg per minute; median duration, 14 days) had higher rate
of adverse events (worsening HF, need for vasoactive
medications, resuscitated cardiac arrest, myocardial in-
farction, and total mortality; 85.3% vs 64.5%; P = .0006)
and a higher mortality (70.5% vs 37.1%; P = .0001)
compared with the others.25 Further studies and a meta-
analysis confirmed the increased risk of death associated
with dobutamine infusion.26 It is, however, likely that this
occurs mostly with prolonged infusions and/or the
administration of relatively high doses (ie, N5 μg/kg per
minute). Despite its limitations and although this may be
related to the lack of valid alternatives, dobutamine
remains useful for the short-term treatment of patients
with low cardiac output and peripheral hypoperfusion.
Dopamine
When administered at low doses (0.5-3 μg/kg per
minute), dopamine stimulates dopaminergic 1 and
dopaminergic 2 receptors with splanchnic and renal
vasodilation and an increase in renal blood flow. At
higher doses (3-5 μg/kg per minute), dopamine binds
to β1-receptors and increases norepinephrine release
from sympathetic nerve terminals with an increase in
cardiac contractility and heart rate. At even higher
doses (5-20 μg/kg per minute), α1-Receptor–mediated
vasoconstriction dominates with an increase in periph-
eral vascular resistance.27,28
Dopamine is often used to improve diuresis and renal
blood flow in patients with acute HF or at risk for acute
renal failure. In the recently completed Dopamine in Acute
Decompensated Heart Failure trial, 60 patients with acute
HF were randomized to a continuous 8-hour infusion of
either high-dose furosemide (20 mg/h) or low-dose
furosemide (5 mg/h) combined with low-dose
dopamine.29 Both strategies had a similar effect on
diuresis and dyspnea score. Worsening renal function,
defined as a greater than 0.3 mg/dL rise in serum creatinine
from baseline to 24 hours, was more frequent in the high-
dose diuretic group (30%) than in the dopamine group
(6.7%). Length of stay and 60-day mortality or rehospi-
talization rates were similar between the 2 groups. The
study has some limitations, in particular, the small numberof patients, which limits the ability to draw conclusions
regarding the effects on outcomes. However, it confirms
previous studies regarding the favorable effects of
dopamine on diuresis and renal function with a prospec-
tive, randomized study design.29
The favorable results of small mechanistic studies are,
however, contradicted by studies aimed at the assessment
of the effects on outcomes. A meta-analysis of 61 trials,
including 3359 patients at risk for acute renal failure, has
shown an increase in diuresis during the first 24 hours of
dopamine administration in the absence of any difference
in serum creatinine levels, rate of acute renal failure
development, and short-term mortality but with a tendency
toward a greater rate of adverse events.30 Thus, despite
favorable data from small studies, no data have shown
favorable effects of dopamine infusion on major out-
comes, defined as mortality, rehospitalizations, or preven-
tion of renal replacement therapy.18Phosphodiesterase inhibitors
Phosphodiesterase 3 inhibitors (PDE3-Is) increase
cAMP level by inhibiting its breakdown within the cell.
Thus, their mechanisms of action and effects on cardiac
function are similar to those of β1-AR agonists. The
PDE3-Is act, however, downstream the β1-AR; and thus,
their actions are independent from β1-ARs density but not
from cAMP concentrations and from ongoing β-blocker
therapy.18,22 Phosphodiesterase inhibitors (PDE-Is) have
also greater vasodilating activity, compared with dobuta-
mine, mediated by direct effects of cAMP in the vascular
smooth muscle cells. This vasodilatory activity may cause
hypotension and further peripheral and coronary hypo-
perfusion in patients who are already hypotensive at
baseline and with low ventricular filling pressure.6,10,11
Similar to dobutamine, their administration has been
associated with an increased risk of death.26
The OPTIME-HF was the only study in which the
effects of a PDE-I (milrinone) were assessed with a
prospective, double-blind, parallel group, randomized,
placebo-controlled design. The trial included 951 patients
admitted for an exacerbation of HF.31 No difference was
found between the milrinone and placebo groups with
respect of the total number of days hospitalized for
cardiovascular causes, inhospital mortality, 60-day mor-
tality, or the composite incidence of death or readmission.
However, patients on milrinone, compared with those on
placebo, had more treatment failures caused by adverse
events as well as episodes of sustained hypotension
requiring intervention (10.7% vs 3.2%; P b .001) and new
atrial arrhythmias (4.6% vs 1.5%; P = .004).31 A further
analysis showed that milrinone may increase mortality in
the patients with concomitant coronary artery disease with
no effect on outcomes in patients with nonischemic
cardiomyopathy.32
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placebo-controlled trial, patients with an indication for IV
inotropic therapy were excluded from the trial. Thus, the
patients who should have gained the greatest benefit from
inotropic therapy (ie, with shock or hypotension) were
excluded from the study. This was also shown by the
relatively high blood pressure of the patients studied (120/
71 mm Hg) as well as by the low proportion of patients on
concomitant dobutamine therapy (9.3% on placebo vs
11.5% on dobutamine).31
An increase in mortality in the patients on PDE-Is has
been consistently shown by long-term studies with the oral
agents.33-35 However, these data were collected before the
introduction of β-blockers in HF treatment; and lower
doses of PDE-Is might have had a better benefit-to-risk
ratio. However, even a more recent placebo-controlled
trial in which the effects of low doses of oral enoximone
have been assessed in 1854 patients with advanced HF on
current medical treatment, including β-blockers, has failed
to show any effect of enoximone on mortality, hospital-
izations, symptoms, and exercise capacity.36 Although
these neutral results may be interpreted as more favorable,
compared with previous negative trials, they confirm the
low benefit-to-risk ratio of PDE-Is in the treatment of
advanced HF.
Calcium sensitizers
Levosimendan is the prototype of calcium sensitizers. It
has 2 main mechanisms of action: calcium sensitization of
the contractile proteins and opening of adenosine
triphosphate (ATP)–dependent K+ channels. Enhanced
Ca2+ binding by troponin C may increase cardiac
contractility in the absence of any increase in intracellular
Ca2+ concentration, a potentially untoward mechanism
increasing myocardial energy expenditure and arrhythmic
risk. The opening of K+ channels in vascular smooth
muscle cells causes arteriolar and venous dilation.
Phosphodiesterase type 3 inhibition is also present, but
this effect has been described as milder compared with the
other 2 mechanisms of action of this agent.18
The favorable effects on mortality of levosimendan,
suggested by early trials, were not confirmed in 2 more
recent randomized controlled trials: survival of patients
with acute HF in need of intravenous inotropic support
(SURVIVE)37 and randomized multicenter evaluation of
intravenous levosimendan efficacy versus placebo in the
short-term treatment of decompensated heart failure II
(REVIVE-II).38 The primary end point of REVIVE-II was
the improvement in the signs and symptoms of HF at 24
hours, 48 hours, and 5 days. Levosimendan treatment was
associated with a favorable effect on the primary end point
(P = .015) with a larger decline in brain natriuretic peptide
(BNP) plasma levels and a shorter (2 days) duration of
hospital stay. However, no difference in 90-day mortality
was found (35 deaths on placebo, 12%, vs 45 deaths, 15%,on levosimendan; P = .210). Moreover, treatment with
levosimendan was associated with higher rate of adverse
effects, compared with placebo: hypotension (50% vs
36%), ventricular tachycardia (24% vs 17%), and atrial
fibrillation (8% vs 2%).38
In the SURVIVE trial, 1327 patients with acute HF
needing inotropic support were randomized to levosimen-
dan or dobutamine.39 Mortality at 180 days (primary end
point) was similar between the 2 study groups (26% with
levosimendan vs 28% with dobutamine; P = .40). Brain
natriuretic peptide decrease was larger in the patients
assigned to levosimendan; and the rate of worsening HF
was greater in the dobutamine group, whereas the rate of
new onset atrial fibrillation was greater in the levosimen-
dan group.37
Peripheral vasodilation and hypotension are potential
major limitations of levosimendan. The decrease in blood
pressure and the increase in heart rate from baseline were
larger with levosimendan, compared with placebo, in
SURVIVE. It is possible that the design of this trial
favored the side effects, namely, hypotension, of levosi-
mendan. First, an insufficient response to diuretics and/or
vasodilators was an inclusion criterion of the study so that
the study drug could be administered only to patients
already on maximal doses of diuretics and/or vasodilators.
Second, a relatively high dose of levosimendan, 12 μg/kg
IV, had to be administered as a bolus before the continuous
infusion at 0.1 μg/kg per minute.37
Few data are available about oral levosimendan. In a
recent randomized, double-blind, multicenter trial, 307
patients with HF (New York Heart Association [NYHA]
class IIIB-IV, LVEF ≤30%) on angiotensin-converting
enzyme inhibitors and β-blockers were randomized to
placebo or oral levosimendan (1 mg once or twice daily for
at least 180 days). There were no differences between
levosimendan and placebo in symptoms and episodes of
worsening HF (P = .567), but there was an improvement in
the Minnesota Living with Heart Failure quality-of-life
score (P b .001) and a decrease in N-terminal pro-BNP
(−30% to 40%; P b .001) in the levosimendan group.41Agents under investigation
Na+/K+–adenosine triphosphatase inhibitors
Istaroxime is the prototype of a new class of agents,
which have both positive inotropic activity, due to
inhibition of Na+-K+ adenosine triphosphatase (ATPase)
located at the sarcolemma, with a secondary increase in
cytosolic calcium concentration as well as lusitropic
activity, through sarcoplasmic reticulum calcium ATPase
(SERCA) activation with increased calcium uptake by the
SR and improved relaxation (Table 3).40
The Haemodynamic effects of istaroxime, a novel
lusitropic agent, in patients with LV systolic dysfunction
Table 3
Inotropic agents under investigation
Drug Mechanism
Na+/K+-ATPase inhibitors
Istaroxime
Sarcolemma Na+-K+ pump inhibition: cytosolic calcium increase
SERCA2a stimulation: increased uptake of cytosolic calcium into
the SR during diastole: better relaxation and increased calcium
release during systole
Cardiac myosin activators
Omecamtiv mecarbil
Myosin stimulation: increased actin myosin interaction, systolic
ejection phase lengthening, no change in ejection rate, or intracellular
calcium changes
RyR stabilizers
JTV-519, S107
Promotes RyR2/calstabin 2 interaction, no SR calcium leakage
SERCA2a activators
SERCA2a adenoassociated viral vector, other agents
SERCA2a up-regulation: increased uptake of cytosolic calcium into the
SR during diastole: better relaxation and increased calcium release
during systole
Metabolic modulators
Perhexiline, trimetazidine, ranolazine, glucagon-like peptide 1
Carnitine palmitoyl transferase 1 inhibition: myocardial substrate shift
from FFAs to glucose; other mechanisms (ranolazine, Glucagon-like Peptide-1)
Urocortin 2 Myocardial and vascular CRF2 receptors
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HF) trial has assessed the hemodynamic effects of istaroxime
in 120 patients admitted for acute HF with LVEF 35% or less
and a SBP between 90 and 150 mm Hg. Patients were
randomized 3:1 to a 6-hour continuous infusion of 3 different
doses of istaroxime (0.5, 1.0, and 1.5 μg/kg per minute) or
placebo. Istaroxime compared with placebo was associated
with pulmonarywedge pressure reduction (primary end point,
P b .05 for all 3 doses), an increase in the cardiac index, and a
decrease in the LV end-diastolic volume (significant only
with the dose of 1.5 μg/kg per minute).41 Istaroxime was also
associated with a dose-dependent increase in the E' velocity
(P = .043) and the Ewave deceleration time (P = .001), with a
decrease in the E/E' ratio (P = .047).42 These favorable
hemodynamic effects were attended, as a peculiarity of this
agent among the other inotropic drugs, by an increase in the
blood pressure, potentially useful for the treatment of the
patients with hypotension, and a decrease in heart rate,
potentially useful in patients with coronary artery disease as a
mechanism to improve coronary blood flow and reduce
myocardial oxygen consumption. More studies are needed to
verify the effects of this agent in patients with HF and low
cardiac output.
Cardiac myosin activators
These agents act on cardiac myosin enhancing the
transition of the actin-myosin complex from the weakly
bound to the strongly bound configuration, thus
increasing the number of myosin heads interacting
with the actin filament. The rate of nonproductive
ATP hydrolysis is also reduced. Increased actin-myosin
interaction prolongs the duration of systole and, hence,
increases stroke volume in the absence of any change in
intracellular calcium concentrations and in the velocity
of myocardial contraction. This results in an improve-
ment in myocardial systolic function in the absence of
the untoward effects of increased intracellular cAMP and
calcium concentrations.11,43The IV infusion of the myosin activator omecamtiv
mecarbil in 2 experimental models of pacing-induced
LV systolic dysfunction, caused by myocardial infarc-
tion or chronic pressure overload with LV hypertrophy,
respectively, was associated with a 44% ± 6.5% increase
in stroke volume and a 22% ± 2.8% increase in cardiac
output with a concomitant 15% ± 3.0% reduction in
heart rate, no change in blood pressure, and a decline in
LV end-diastolic pressure. Differently from dobutamine,
omecamtiv mecarbil did not increase LV dP/dt but
increased LV systolic ejection time (+26% ± 2.9%) and
did not increase myocardial oxygen consumption.44
These results in animal models have been confirmed
by preliminary findings in patients with chronic HF and
low LVEF showing a concentration-dependent increase
in LV systolic ejection time, stroke volume, and cardiac
output and a reduction in heart rate after omecamtiv
mecarbil administration.43
Despite the favorable effects on myocardial oxygen
consumption, lengthening of the systolic ejection time
may have untoward effects on coronary perfusion because
it may cause a decrease in the diastolic time duration.
However, no untoward effects on exercise tolerance have
been shown after omecamtiv mecarbil administration to
patients with ischemic cardiomyopathy in a study
presented at the 2009 European Society of Cardiology
congress.45 Omecamtiv mecarbil looks to be a potentially
promising agent for the treatment for patients with HF, and
a program of clinical studies is ongoing.43
Ryanodine receptor stabilizers
In the failing heart, sympathetic activation leads to
excessive protein kinase A–mediated ryanodine receptor
(RyR) 2 phosphorylation, dissociation of the stabilizing
unit calstabin 2 (also known as FKBP12.6), and calcium
leakage from the SR. Therefore, stabilization of RyR2
may represent a novel therapeutic strategy for the
treatment of HF.46,47 The 1,4-benzothiazepines JTV-519
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interaction and prevent SR calcium leakage. In an animal
models of myocardial infarction– and pacing-induced
HF, the 1,4-benzothiazepine derivative JTV-519 in-
creased calstabin 2 binding to RyR2, inhibited SR
calcium leakage, and prevented the deterioration of
cardiac function.48 These results suggest that these agents
may be useful for the treatment of HF, including HF
caused by predominant diastolic dysfunction. Further
investigations are needed.
SERCA2a activators
Sarcoplasmic reticulum calcium ATPase (SERCA) 2a is
the enzyme responsible for the reuptake of calcium into the
SR during the early diastolic phase. It is down-regulated in
the failing heart, and this accounts for the increased free
intracytoplasmatic calcium and reduced calcium storage in
the SR with reduced calcium release from the SR and,
hence, less force of contraction, at the next systole. These
mechanisms cause impaired cardiac function and tachyar-
rhythmias. Sarcoplasmic reticulum calcium ATPase 2a has,
thus, become a major target of HF treatment.
An adenoassociated viral vector carrying the gene for
SERCA2a has been studied by intracoronary injections in 9
patients with advancedHF (NYHA class III/IV, LVEF≤30%,
peak oxygen consumption per unit time [VO2] b16 mL/kg per
minute, with maximal pharmacologic and device therapy).49
At 6- to 12-month follow-up, adeno-associated viral vector/
SERCA2a demonstrated evidence of biologic activity across
several symptomatic, functional, and structural efficacy end
points without adverse effects. These findings have supported
the initiation of the phase 2 double-blind, placebo-controlled
portion of the study.
In addition to gene therapy, a class of novel small
molecules, acting as allosteric compounds, is under
development and has been shown to modulate SERCA2a
activity and increase peak VO2 and contractility without
increasing energy use, making them important candidates
as new IV inotropic drugs.11
Metabolic modulators
These agents cause a shift in energy use from free fatty
acids (FFAs) to glucose. Free fatty acids are the preferred
metabolic substrate used by the heart to produce energy.
Their oxidation generates a greater amount of ATP
compared with the glycolytic pathway, although a greater
amount of oxygen is also required; and thus, the ATP/
oxygen ratio, that is, the efficiency of the process, is lower
when FFAs, rather than glucose, are used.50 Metabolic
modulators were initially developed as a treatment for
patients with recurrent episodes of angina. However, these
drugs became of interest also for HF treatment as a shift in
myocardial metabolism from predominant FFAs to glucose
uptake is potentially beneficial also in these patients.Perhexiline is an inhibitor of carnitine palmitoyl
transferase 1, an enzyme playing a critical role for
mitochondrial FFA uptake. It has been associated with
serious adverse effects, such as hepatotoxicity and
peripheral neuropathy, which can be, however, avoided
by careful dose titration and monitoring of drug plasma
levels.51 Eight weeks of treatment with perhexiline were
associated with an improvement in peak VO2 (P b .001),
quality of life (P = .04), and LVEF (P b .001), with no
significant adverse effects, compared with placebo.52
Other agents active on myocardial metabolism and
potentially useful for HF treatment include trimetazidine
and ranolazine. Trimetazidine administration has been
associated with an increase in the phosphocreatine to ATP
ratio, assessed by 31P-magnetic resonance spectroscopy,
with a reduced FFAs oxidation and unchanged myocardial
oxidative rate, implying increased glucose oxidation.53,54
Favorable effects on multiple parameters related to LV
function and exercise capacity have been shown in relatively
small studies. In a recent meta-analysis of 17 placebo-
controlled, randomized trials including 955 patients with
HF, trimetazidine administration has been associated with
an improvement in LVEF, a decrease in LV end-systolic
volume, and an improvement in NYHA functional class and
exercise duration. Trimetazidine administration was also
associated with a lower all-cause mortality (relative risk,
0.29; 95% confidence interval [CI], 0.17-0.49) and a lower
rate of cardiovascular events and hospitalizations.55 These
data were, however, collected mainly in relatively small
studies, often conducted in single centers. More studies,
namely, larger multicenter randomized clinical trials, are
warranted to confirm its effects in HF.
Ranolazine acts through the inhibition of late sodium
channel current, thus preventing intracellular calcium
overload during myocardial ischemia, and through the
inhibition of FFAs oxidation. It is now indicated for the
treatment of angina. However, its beneficial effects on LV
diastolic function, likely mediated by the prevention of
intracellular Ca2+ overload, have also been shown.56,57 It
may, therefore, be potentially useful for the treatment of
HF, also when caused by LV diastolic dysfunction.
Beneficial effects on LV remodeling and myocardial
fibrosis have also been shown in experimental models.58
Differently from dobutamine, it has increased myocardial
mechanical efficiency in a dog model of HF.59
Glucagon-like peptide 1 is a relatively new antidiabetic
agents. Beneficial effects of its administration on LVEF
and exercise tolerance have been shown in patients with
HF in some,60,61 but not all,62 of the studies. As with the
previous compounds, a larger controlled trial with clinical
end points is needed.
Urocortin
Urocortin is a vasoactive peptide belonging to the
corticotrophin-releasing factor (CRF) peptide family.63
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act through G-protein–coupled receptor subtypes, CRF1
and CRF2. Corticotrophin-releasing factor 1 receptors are
localized almost exclusively in the central nervous system,
whereas CRF2 receptors are present both in the brain and in
peripheral tissues, including the myocardium and blood
vessels where they are strongly expressed. Differently from
urocortin 1, which binds similarly to both receptor subtypes,
urocortins 2 and 3 are selective for the CRF2 receptors.64,65
The administration of urocortins, namely, urocortins 2 and 3,
in experimental models of HF has been associated with an
increase in cardiac output and a decline in peripheral
resistance, left atrial pressure, and mean arterial pressure. It
has induced a persistent, dose-dependent decrease in plasma
vasopressin, renin activity, aldosterone, natriuretic peptides,
and endothelin 1 plasma levels, with an acute rise in
adrenocorticotrophic hormone and cortisol levels. Lastly, a
dose-dependent, sustained increase in diuresis, natriuresis,
and creatinine clearance was found.65-67 A favorable inter-
actionwith diuretic treatmentwith increased diuretic respon-
siveness and blunting of furosemide-induced renin increase
has also been shown.68 Urocortin 3 (stresscopin) is now
undergoing further assessment in larger clinical trials in
patients with HF.Conclusions and future perspectives
Treatment of patients with acutely decompensated HF
and signs of low cardiac output and end-organ dysfunction
remains one of the major challenges of current cardiovas-
cular therapy. Current inotropic agents have short-term
hemodynamic effects but may also favor arrhythmias,
myocardial ischemia, and cardiac damage. Inotropic agents
have evolved through the enthusiasm for increased
contractility and the disappointment from increased mor-
tality. New, potentially favorable mechanisms of action
include a reduction in heart rate, a lack of hypotensive
effects, and more efficient myocardial contraction with less
oxygen consumption. New agents seem to possess some, if
not all, of these characteristics. Only properly designed
controlled studies, also powered to assess medium- and
long-term effects and safety, will show if newer inotropic
agents may improve the treatment- of patients with
advanced HF.
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